or
Bookmark and Share
   
Document Number
US Patent 4679371
Issued Date
July 14, 1987
Link
Inventors
Map
Abstract
A profile consisting of two sections (1, 2) joined together. One section (1) is an open hollow section with an inner contour which is uniform with and somewhat bigger than the outer contour of the other section (2) and where the opening (4) is arranged so that two identical profiles can be telescoped into each other. According to the invention the other section (2) is solid or a closed hollow section. The opening (4) of the open hollow section (1), has a width which is somewhat bigger than the wall thickness of the hollow section (1) in an area (5), which is situated on the opposite side relative to the opening (4) of the connection (3) between the sections (1, 2). Thus, it is achieved that the open hollow sections (1) of the profiles substantially, completely surround the other sections (2) of the profiles, respectively, when two identical profiles are telescoped into each other.
Drawing
Profile - US Patent 4679371 Drawing
Drawing from US Patent 4679371
Tags:
Description:
Amusing 0%
Clever 0%
Complex 0%
Efficient 0%
Historic 0%
Important 0%
Innovative 0%
Interesting 0%
Practical 0%
Simple 0%
Number of Claims:
4
Comments:
no comments yet
Owner
Published
July 14, 1987
Application Number
06/589,080
Filed
February 2, 1984
US Classification
52/574   52/732.1
Int'l Classification
E04G   1/15   (20060101)   E04G   1/00   (20060101)   E04C   3/06   (20060101)   E04C   3/30   (20060101)   E04C   3/00   (20060101)   E04C   3/04   (20060101)   E04C   3/32   (20060101)  
Assistant Examiner
Attorney/Law Firm
Priority Data
Jun 04, 1982 [SE] 8203465
USPTO Field of Search
52/731   52/284   52/282   52/574   52/732   52/730   52/588  
Related Patents
6255315 - Alpha 1a adrenergic receptor antagonists - Owned by Merck & Co., Inc. (Rahway, NJ)

This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as alpha 1a adrenergic receptor antagonists. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha relductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia are achieved.

Claims
Description
About| FAQs| Terms & Disclaimer| Link to Us| Contact Us